I'm LongbridgeAI, I can summarize articles.Eli Lilly shares rose 1.34% to $1,153.50 following positive pipeline data for retatrutide and Foundayo presented at EASD 2026. The stock also benefited from strong Q2 2026 results, with revenue up 48% year-over-year to $22.97 billion. Consequently, the company raised its full-year 2026 revenue guidance to $85-$87 billion, reinforcing investor confidence in its commercial execution.
Shares of Eli Lilly and Company (NYSE:LLY) are trading higher Tuesday morning following positive previews of its late-stage obesity and diabetes pipeline.
- Eli Lilly stock is trading near recent highs. What’s next for LLY stock?
EASD 2026 Pipeline Previews Highlight Retatrutide and Foundayo Momentum
The morning upside follows Lilly’s announcement that it will present pivotal Phase 2 and Phase 3 data across its cardiometabolic portfolio at the 62nd European Association for the Study of Diabetes Annual Meeting in Milan.
Headline presentations include Phase 3 TRIUMPH-2 results for retatrutide, an investigational triple hormone receptor agonist, which demonstrated up to 20.8% average weight loss (49.6 lbs) and a 1.6% A1C reduction at 80 weeks in adults with obesity and type 2 diabetes.
Additionally, Phase 3 ACHIEVE-4 data for Foundayo (orforglipron), Lilly’s daily oral GLP-1, demonstrated a 23% lower risk of MACE-3 cardiovascular events versus insulin glargine, while Phase 1 results for eloraTZP (combining amylin agonist eloralintide with tirzepatide) showed 17% weight loss over 16 weeks.
August Earnings Beat and Raised Full-Year Guidance Anchor Fundamentals
The morning’s positive tone builds on exceptional second-quarter 2026 financial results reported on August 5. Lilly delivered worldwide revenue of $22.97 billion, up 48% year-over-year, driven by explosive demand for Mounjaro ($9.9 billion) and Zepbound ($4.9 billion), alongside non-GAAP EPS of $8.38 that comfortably topped consensus estimates.
Reiterating the company’s strong trajectory, Chair and CEO David A. Ricks stated: “Lilly’s momentum continues, as we delivered 48% revenue growth and raised our full-year guidance.”
Lilly boosted its full-year 2026 revenue outlook to a range of $85 billion to $87 billion (up from $82 billion to $85 billion), reinforcing Wall Street’s confidence in Lilly’s long-term commercial execution and manufacturing scaling.
LLY Shares Gain Tuesday Morning
LLY Price Action: Eli Lilly shares are trading higher by 1.34% at $1153.50 during premarket trading on Tuesday, according to Benzinga Pro data.
Read Also: EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
Image: Shutterstock